Navigation Links
NewGen Therapeutics Reports Potent Anticancer Activity for Targeted Brain Cancer Drug, NT-113
Date:11/25/2013

MENLO PARK, Calif., Nov. 25, 2013 /PRNewswire/ -- NewGen Therapeutics, Inc. today announced that preclinical data demonstrate a high therapeutic potential for the company's targeted therapeutic candidate for brain cancer, NT-113. Data from in vivo studies of the experimental drug demonstrated potent anticancer activity and improved survival in a mouse intracranial xenograft model implanted with both EGFR (epidermal growth factor)-amplified and EGFRvIII-mutated glioblastoma cell lines.

(Logo: http://photos.prnewswire.com/prnh/20130408/SF90357LOGO)

The findings were presented by scientists from the Brain Tumor Research Center at the University of California, San Francisco (UCSF) as an oral podium presentation entitled "Preclinical evaluation of NT-113, a novel erbB inhibitor optimized for CNS (central nervous system) biodistribution" at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology, on November 24, 2013 in San Francisco, California.

"Given NT-113's robust anti-cancer activity in multiple intracranial human glioblastoma xenograft studies, excellent pharmacokinetics and very high capacity to cross the blood brain barrier, we plan to initially explore this potential targeted medicine for patients with glioblastoma and non-small cell lung cancer with brain metastases," said Harry D. Pedersen, chief executive officer of NewGen Therapeutics. "EGFR alterations drive many solid tumors to grow and spread.  Overexpression and/or mutations of EGFR occur in 40-60% of glioblastoma patients and 40-80% of non-small cell lung cancer patients, most of whom eventually develop brain metastases. Focusing on patients with EGFR over-expression or mutations in these studies should result in higher response rates, improved survival and more rapid approval timelines."

Mr. Peders
'/>"/>

SOURCE NewGen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... 2014  Indianapolis interventional medical device maker ... -based 3D visualization leader Synaptive Medical ... Annual Meeting that they have joined forces to ... collaboration is the first of its kind and ... outcomes. NICO,s BrainPath® interventional access technology and Synaptive,s ...
(Date:10/20/2014)... , Oct. 20, 2014   BioNano Genomics ... system: the ability to collect human data at 30X depth, ... single chip.  This new capability was established and demonstrated for ... Irys TM System and will be rolled ... months. BioNano will be showcasing this advancement at the ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... WASHINGTON, Nov. 16, 2011 The proliferation of brand ... generics to more expensive brands, will increase costs by ... for employers, unions, and state employee plans, according to ... Pharmaceutical Care Management Association (PCMA).  The use of ...
... Nov. 16, 2011   The proliferation of brand drug ... to more expensive brands, will increase costs by $308 ... unions, and state employee plans, according to new research ... Management Association (PCMA).  The use of these promotions ...
Cached Medicine Technology:Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $1 Billion in New Jersey 2Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $308 Million in Arkansas 2
(Date:10/22/2014)... October 22, 2014 Medical ... company, is happy to announce that our co-founder ... Staffing Industry Analysts’ Staffing 100 for 2014. Anderson ... “100 most influential people in the staffing industry,” ... Solutions, the 13th-largest healthcare staffing company in the ...
(Date:10/22/2014)... October 22, 2014 Shriners Hospitals for ... will change the current location of Shriners Hospitals for ... Limestone across from the University of Kentucky Albert B. ... ambulatory care center, owned and operated by Shriners Hospitals ... needs of children and their families well into the ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Best Cheap ... in the world. The site has recently announced that ... hosting supplier for people from around the world. , ... in operation today and is providing various kinds of ... the company insists on offering excellent customer service and ...
(Date:10/22/2014)... October 22, 2014 Richard Carlson, Managing ... industry leader with over 25 years experience. Mr. ... in the areas related to EDI, B2B Commerce, RFID ... an Editorial Advisory Board member for Pharmaceutical Commerce Magazine ... Blue Fin Group is a management and technology consulting ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... injuries accounted for 3.5 percent of high school ... first study to examine rare injuries and conditions ... eye injuries, dental injuries, neck and cervical injuries ... in high morbidity, costly surgeries and treatments or ...
... to President-elect Barack Obama, American Association of Homes and Services for ... ways that the Obama administration can make both short-term gains and ... vulnerable people. , , These ... Force: Create Jobs in Aging Services; , Construct ...
... glasses a day linked to atrial fibrillation, study finds ... woman can have up to two drinks a day without ... a new study finds. , A group including Dr. Christine ... mined the data of the large-scale Women,s Health study, looking ...
... USC Viterbi School of Engineering has led to significant ... California safety net hospitals, allowing "many more hours of ... the program, the work will be expanded to include ... School,s Epstein Department of Industrial and Systems Engineering began ...
... COSTA MESA, Calif., Dec. 2 TROY Group, ... on-demand printing,solutions, announces the first digital printer for ... bond paper. The TROY SecureRx,printer allows healthcare providers ... complying with the security regulations,established by the Center ...
... Treadmill Desks May Increase Production of Small Blood Vessels in the Brain ... ... recent years have shown that walking on a regular basis lowers an ... now uncovering the exact reasons why. A recent study conducted at the ...
Cached Medicine News:Health News:Light Drinking Poses No Heart Risk for Women 2Health News:Operations engineering for more efficient operating rooms 2Health News:Operations engineering for more efficient operating rooms 3Health News:TROY SecureRx Revolutionizes Prescription Printing 2Health News:TROY SecureRx Revolutionizes Prescription Printing 3Health News:TROY SecureRx Revolutionizes Prescription Printing 4Health News:Employees Have Yet Another Reason To Lose Their Office Chairs In Favor Of A Treadmill Desk: Their Brain 2Health News:Employees Have Yet Another Reason To Lose Their Office Chairs In Favor Of A Treadmill Desk: Their Brain 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: